Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Perspective Therapeutics (NYSE American: CATX) announced that CEO Thijs Spoor will present at the 44th Annual J.P.
Rhea-AI Summary
Perspective Therapeutics (NYSE American: CATX) announced that CEO Thijs Spoor will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026.
The company presentation is scheduled for 2:15–2:55 p.m. PT at The Westin St. Francis Hotel and will cover Perspective's radiopharmaceutical development programs targeting cancers throughout the body.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CATX
In the Dec 18 session, CATX gained 3.09%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference
- Presentation date
- January 14, 2026
- J.P. Morgan Healthcare Conference company presentation
- Presentation time start
- 2:15 p.m. PT
- J.P. Morgan Healthcare Conference slot
- Presentation duration
- 40 minutes
- 2:15–2:55 p.m. PT J.P. Morgan session
Historical Context
-
Acceptance of [212Pb]VMT-α-NET data for ASCO-GI 2026 presentation.
-
Announcement of participation in two December healthcare investor conferences.
-
Q3 2025 results with clinical progress and funding into late 2026.
-
Planned investor meetings and fireside chat at November conferences.
-
Notice of upcoming Q3 2025 earnings release and business update.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
radiopharmaceutical medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14, 2026, at 2:15 p.m. PT.
44th Annual J.P. Morgan Healthcare Conference – Company Presentation
Date: Wednesday, January 14, 2026
Time: 2:15 - 2:55 p.m. PT
Location: The Westin St. Francis Hotel, San Francisco, CA
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the ability of the Company's proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company’s prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations; and other statements that are not historical fact.
These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.